Guggenheim Starts Tyra Biosciences, Inc. (TYRA) at Buy on Strength of Lead Drug Dabogratinib
TheFly reported on April 15 that Guggenheim Securities initiated coverage of TYRA with a Buy rating and set a price target of $54.
Tyra Biosciences Inc. (TYRA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 28,800 | $1,103,040 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.13 | 11,813 | $119,665.69 | 10,259,291 | 2025-06-16 | Filing | |
| $10.20 | 120,167 | $1,225,703.40 | 10,247,478 | 2025-06-13 | Filing | |
| $10.20 | 31,307 | $319,331.40 | 10,127,311 | 2025-06-12 | Filing | |
| $10.19 | 186,850 | $1,904,001.50 | 10,096,004 | 2025-06-09 | Filing | |
| $10.04 | 213,334 | $2,141,873.36 | 9,909,154 | 2025-06-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $36.97 | 14,295 | $528,506.16 | 28,231 | 2026-03-25 | Filing | |
| $33.37 | 5,872 | $195,928.68 | 146,981 | 2026-02-12 | Filing | |
| $31.50 | 2,128 | $67,035.83 | 152,853 | 2026-02-12 | Filing | |
| $29.08 | 1,017 | $29,575.17 | 154,981 | 2026-01-12 | Filing | |
| $28.44 | 6,983 | $198,610.49 | 155,998 | 2026-01-12 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,823,425 | $146,437,178 | 96.97% | |
| 2. | 1,125,970 | $43,124,651 | 0% | |
| 3. | 750,000 | $28,725,000 | 37.76% | |
| 4. | 632,432 | $24,222,146 | 0.02% | |
| 5. | 247,270 | $9,470,441 | 0% |
News See All
Top 10 AI-Powered Biotech Stocks to Buy Right Now
Franklin Equity reported on February 16 that, following a protracted period of uncertainty in the previous year, the biotechnology sector has entered 2026 on a firmer and more stable foundation.
Oppenheimer's Favorite Stocks For Next 12 Months: Top 32 Stock Picks
The tail end of August is appearing to turn a fresh page for Wall Street.
16 Most Promising Long-Term Stocks According to Analysts
In this piece, we will take a look at the 16 most promising long-term stocks according to analysts.
Hedge Fund Resource Center